Practices, knowledge, and attitudes of community pharmacists towards dispensing drugs during the COVID-19 pandemic: A cross sectional study from Jordan

Main Article Content


COVID-19, Pandemic, Community pharmacist, Knowledge, Attitude, Practice, Azithromycin, Hydroxychloroquine , Antibiotic


Background: Pharmacists have an important role in providing correct information, education, and counseling to the public during the COVID-19 pandemic and other health crisis. In order to perform their duties in a correct manner, they must receive adequate and evidence-based information from official resources. Objectives: The objectives of the study were to examine the practices of community pharmacists towards dispensing drugs during the COVI-19 pandemic and assess their knowledge concerning the safety and efficacy of these drugs in managing the COVID-19 infection. Methods: This was a webbased cross-sectional study conducted through the distribution of the questionnaire via the social media through a google form. The drugs examined were azithromycin, hydroxychloroquine, dexamethasone, and certain antiviral drugs. Results: A total of 485 community pharmacists responded to the questionnaire. Pharmacists dispensed these medications based on the physician’s orders, 420 (86.6%), according to the pharmacist´s recommendations 327 (67.4%), or upon patient´s request 278 (57.3%). Azithromycin was the most dispensed drug and two thirds of the pharmacists dispensed drugs more than 10 times. Community pharmacists did not possess adequate knowledge concerning the effectiveness and safety of the drugs in the management of COVID-19 infection. In the multivariate linear regression analysis; education, type of university, and the average number of daily customers were statistically significant, p values: 0.004, 0.002, and 0.016, respectively. Pharmacists did not have a positive attitude towards dispensing drugs based on their own recommendations. More than half of the pharmacists agreed that they thought it was a correct decision to give these drugs based on their own judgment. Conclusion: Community pharmacists should not receive information from non-official sources. Strict regulations and implementation of disciplinary actions against pharmacists that dispense prescription only drugs based on their medical judgment are necessary to stop this illegal behavior. A proactive role demonstrated by the pharmacists and based on scientific facts will reduce misconceptions and hazardous behavior of self-medication using prescription only drugs based on rumors and fictitious news.

Abstract 777 | PDF Downloads 108


1. Sen Gupta PS, Biswal S, Panda SK, et al. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin. J Biomol Struct Dyn. 2022;40(5):2217-2226.
2. Lovato A, de Filippis C, Marioni G. Upper airway symptoms in coronavirus disease 2019 (COVID-19). Am J Otolaryngol.2020;41(3):102474.
3. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-220.
4. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, et al. A comprehensive review of COVID-19 characteristics. Biol Proced Online.2020;22:19.
5. Varghese GM, John R, Manesh A, et al. Clinical management of COVID-19. Indian J Med Res. 2020;151(5):401-410.
6. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes ofHealth; [cited 2022 June 1]. Available from:
7. Ravari AF, Jin S, Kachouei FH, et al. Systemic corticosteroids for management of COVID-19: Saving lives or causing harm? Int J Immunopathol Pharmacol. 2021;35:20587384211063976.
8. Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8(8):CD014963.
9. Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration. 2011;81(1):67-74.
10. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2007;51(3):975-81.
11. Recovery Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19: A randomised, controlled, openlabel,platform trial. Lancet. 2021;397(10274):605-612.
12. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228.
13. Ip A, Berry DA, Hansen E, Goy AH, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. PLoS One. 2020;15(8):e0237693.
14. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med.2020;383(21):2030-2040.
15. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511.
16. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(21):2165-2176.
17. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. 2020;173(8):623-631.
18. Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet.2021;397(10279):1063-1074. ttps://
19. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-1629.
20. Hasan S, Siang KC, Merchant H. Is it worth the wait? Should Chloroquine or Hydroxychloroquine be allowed for immediate use in CoViD-19? British Journal of Pharmacy. 2020;5(1).
21. Mendel A, Bernatsky S, Thorne JC, et al. Hydroxychloroquine shortages during the COVID-19 pandemic. Ann Rheum Dis.2021;80 (3):e31.
22. Yusuf IH, Sharma S, Luqmani R, et al. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31(6):828-845.
23. McGhie TK, Harvey P, Su J, et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.Clin Exp Rheumatol. 2018;36(4):545-551.
24. Nunnally JC, Bernstein IH. Psychometric theory. New York: McGraw-Hill. 1994.
25. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench.
26. Hedima EW, Adeyemi MS, Ikunaiye NY. Community Pharmacists: On the frontline of health service against COVID-19 in LMICs. Res Social Adm Pharm. 2021;17(1):1964-1966.
27. Kassem AB, Ghoneim AI, Nounou MI, et al. Community pharmacists’ needs, education, and readiness in facing COVID-19:Actions & recommendations in Egypt. Int J Clin Pract. 2021;75(11):e14762.
28. Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. Res Social Adm Pharm. 2021;17(1):2023-2026. https://doi. org/10.1016/j.sapharm.2020.04.007
29. Non Prescription Drug List. Jordan Food and Drug Administration; [cited 2022 June 1]. Available from:
30. Zaroff JG, Cheetham TC, Palmetto N, et al. Association of Azithromycin Use With Cardiovascular Mortality. JAMA Netw Open.2020;3(6):e208199.
31. Nguyen LS, Dolladille C, Drici MD, et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin:An Analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020;142(3):303-305.
32. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425-1433.
33. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
34. ElGeed H, Owusu Y, Abdulrhim S, et al. Evidence of community pharmacists’ response preparedness during COVID-19 public health crisis: A cross-sectional study. J Infect Dev Ctries. 2021;15(1):40-50.
35. Alnajjar MS, ZainAlAbdin S, Arafat M, et al. Pharmacists’ knowledge, attitude and practice in the UAE toward the public health crisis of COVID-19: A cross-sectional study. Pharm Pract (Granada). 2022;20(1):2628.
36. Nguyen HTT, Dinh DX, Nguyen VM. Knowledge, attitude and practices of community pharmacists regarding COVID-19: A paperbased survey in Vietnam. PLoS One. 2021;16(7):e0255420.
37. Basheti IA, Nassar R, Barakat M, et al. Pharmacists’ readiness to deal with the coronavirus pandemic: Assessing awareness and perception of roles. Res Social Adm Pharm. 2021;17(3):514-522.
38. Basheti IA, El-Hajji F, Nassar R, et al. Pharmacists’ awareness of COVID-19 and perceptions of their roles, barriers, and roles of policymakers: Exploring the Middle East and North Africa (MENA). Int J Clin Pract. 2021;75(6):e14074.
39. Al Mazrouei N, Ibrahim RM, Al Meslamani AZ, et al. The evolving role of community pharmacists during COVID-19 in the UAE;assessing preparedness and knowledge. Int J Pharm Pract. 2021;29(2):137-144.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>